BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.730
+0.250 (16.89%)
At close: Mar 9, 2026, 4:00 PM EDT
1.700
-0.030 (-1.73%)
After-hours: Mar 9, 2026, 6:35 PM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$20,324
Profits / Employee
-$1,843,541
Market Cap
37.83M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Rockwell Medical | 244 |
| Cumberland Pharmaceuticals | 91 |
| Aytu BioPharma | 83 |
| Assertio Holdings | 58 |
| SCYNEXIS | 28 |
| Talphera | 13 |
BTAI News
- 3 days ago - Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga
- 4 days ago - BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga
- 4 days ago - BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - GlobeNewsWire
- 9 days ago - BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript - Seeking Alpha
- 18 days ago - BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - GlobeNewsWire
- 7 weeks ago - Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - GlobeNewsWire